Research graph
References from The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies. Local targets link to admitted publications; unresolved targets remain external evidence.
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · 2023 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Amivantamab plus lazertinib in previously untreated EGFR -mutated advanced NSCLC
10.1056/nejmoa2403614 · 2024 · External reference
Bispecific antibodies in Cancer immunotherapy
10.1177/2515135518763280 · 2018 · External reference
Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances
10.1200/edbk-25-473148 · 2025 · External reference
Bispecific antibodies: advancing precision oncology
10.1016/j.trecan.2024.07.002 · 2024 · External reference
Availability and affordability of oncology drugs in 2012-2021 in China and the United States
10.3389/fonc.2022.930846 · 2022 · External reference
LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation
10.1016/j.immuni.2024.01.010 · 2024 · External reference
Small biotechs versus large pharma: who drives first-in-class innovation in oncology?
10.1016/j.drudis.2022.103456 · 2023 · External reference
The present and future of bispecific antibodies for cancer therapy
10.1038/s41573-024-00896-6 · 2024 · External reference
Combining microenvironment normalization strategies to improve cancer immunotherapy
10.1073/pnas.1919764117 · 2020 · External reference
Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors
10.1158/2159-8290.cd-21-1345 · 2022 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
10.1200/jco.21.00662 · 2021 · External reference
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
10.1016/j.annonc.2023.10.117 · 2024 · External reference
Bispecific antibodies in cancer immunotherapy
10.1016/j.copbio.2019.11.020 · 2020 · External reference
The drug-dosing conundrum in oncology — when less is more
10.1056/nejmp2109826 · 2021 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
T-cell-engaging bispecific antibodies in cancer
10.1016/s0140-6736(23)00521-4 · 2023 · External reference
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
10.1186/s12943-018-0777-1 · 2018 · External reference
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
10.1016/s0140-6736(24)02722-3 · 2025 · External reference
Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC
10.1056/nejmoa2503001 · 2025 · External reference
The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020
10.1016/j.lanwpc.2021.100151 · 2021 · External reference
The changing landscape of clinical trial and approval processes in China
10.1038/nrclinonc.2017.10 · 2017 · External reference
Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions
10.1056/nejmoa2306441 · 2023 · External reference
Advances in the clinical application of bispecific antibodies in cancer therapy
10.1016/j.isci.2025.114203 · 2025 · External reference
